Health-related  ||| S:0 E:15 ||| JJ
quality  ||| S:15 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
life  ||| S:26 E:31 ||| NN
in  ||| S:31 E:34 ||| IN
patients  ||| S:34 E:43 ||| NNS
with  ||| S:43 E:48 ||| IN
rheumatoid  ||| S:48 E:59 ||| JJ
arthritis  ||| S:59 E:69 ||| NN
and  ||| S:69 E:73 ||| CC
in  ||| S:73 E:76 ||| IN
patients  ||| S:76 E:85 ||| NNS
with  ||| S:85 E:90 ||| IN
ankylosing  ||| S:90 E:101 ||| JJ
spondylitis  ||| S:101 E:113 ||| NN
In  ||| S:113 E:116 ||| IN
this  ||| S:116 E:121 ||| DT
review  ||| S:121 E:128 ||| NN
the  ||| S:128 E:132 ||| DT
influence  ||| S:132 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
rheumatoid  ||| S:145 E:156 ||| JJ
arthritis  ||| S:156 E:166 ||| NN
( ||| S:166 E:167 ||| -LRB-
RA ||| S:167 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
and  ||| S:171 E:175 ||| CC
ankylosing  ||| S:175 E:186 ||| JJ
spondylitis  ||| S:186 E:198 ||| NNS
( ||| S:198 E:199 ||| -LRB-
AS ||| S:199 E:201 ||| NNP
)  ||| S:201 E:203 ||| -RRB-
on  ||| S:203 E:206 ||| IN
a  ||| S:206 E:208 ||| DT
wide  ||| S:208 E:213 ||| JJ
range  ||| S:213 E:219 ||| NN
of  ||| S:219 E:222 ||| IN
health-related  ||| S:222 E:237 ||| JJ
quality  ||| S:237 E:245 ||| NN
of  ||| S:245 E:248 ||| IN
life  ||| S:248 E:253 ||| NN
( ||| S:253 E:254 ||| -LRB-
HRQoL ||| S:254 E:259 ||| NNP
)  ||| S:259 E:261 ||| -RRB-
domains  ||| S:261 E:269 ||| NN
will  ||| S:269 E:274 ||| MD
be  ||| S:274 E:277 ||| VB
described ||| S:277 E:286 ||| VBN
.  ||| S:286 E:288 ||| .
The  ||| S:288 E:292 ||| DT
domains  ||| S:292 E:300 ||| JJ
most  ||| S:300 E:305 ||| RBS
frequently  ||| S:305 E:316 ||| RB
studied  ||| S:316 E:324 ||| VBN
are  ||| S:324 E:328 ||| VBP
pain ||| S:328 E:332 ||| NN
,  ||| S:332 E:334 ||| ,
functional  ||| S:334 E:345 ||| JJ
disability ||| S:345 E:355 ||| NN
,  ||| S:355 E:357 ||| ,
fatigue  ||| S:357 E:365 ||| NN
and  ||| S:365 E:369 ||| CC
mental  ||| S:369 E:376 ||| JJ
problems ||| S:376 E:384 ||| NNS
.  ||| S:384 E:386 ||| .
In  ||| S:386 E:389 ||| IN
addition ||| S:389 E:397 ||| NN
,  ||| S:397 E:399 ||| ,
age  ||| S:399 E:403 ||| NN
and  ||| S:403 E:407 ||| CC
socio-economic  ||| S:407 E:422 ||| JJ
aspects  ||| S:422 E:430 ||| NNS
such  ||| S:430 E:435 ||| JJ
as  ||| S:435 E:438 ||| IN
employment  ||| S:438 E:449 ||| NN
and  ||| S:449 E:453 ||| CC
economic  ||| S:453 E:462 ||| JJ
status  ||| S:462 E:469 ||| NN
as  ||| S:469 E:472 ||| IN
well  ||| S:472 E:477 ||| RB
as  ||| S:477 E:480 ||| IN
education  ||| S:480 E:490 ||| NN
affect  ||| S:490 E:497 ||| VB
patient-reported  ||| S:497 E:514 ||| JJ
HRQoL.Although  ||| S:514 E:529 ||| CD
many  ||| S:529 E:534 ||| JJ
studies  ||| S:534 E:542 ||| NNS
have  ||| S:542 E:547 ||| VBP
assessed  ||| S:547 E:556 ||| VBN
the  ||| S:556 E:560 ||| DT
impact  ||| S:560 E:567 ||| NN
on  ||| S:567 E:570 ||| IN
HRQoL  ||| S:570 E:576 ||| JJ
of  ||| S:576 E:579 ||| IN
a  ||| S:579 E:581 ||| DT
single  ||| S:581 E:588 ||| JJ
disease  ||| S:588 E:596 ||| NN
state ||| S:596 E:601 ||| NN
,  ||| S:601 E:603 ||| ,
either  ||| S:603 E:610 ||| CC
RA  ||| S:610 E:613 ||| NNP
or  ||| S:613 E:616 ||| CC
AS ||| S:616 E:618 ||| NNP
,  ||| S:618 E:620 ||| ,
few  ||| S:620 E:624 ||| JJ
studies  ||| S:624 E:632 ||| NNS
have  ||| S:632 E:637 ||| VBP
focused  ||| S:637 E:645 ||| VBN
on  ||| S:645 E:648 ||| IN
a  ||| S:648 E:650 ||| DT
direct  ||| S:650 E:657 ||| JJ
comparison  ||| S:657 E:668 ||| NN
between  ||| S:668 E:676 ||| IN
those  ||| S:676 E:682 ||| DT
both  ||| S:682 E:687 ||| DT
diagnostic  ||| S:687 E:698 ||| JJ
groups ||| S:698 E:704 ||| NNS
.  ||| S:704 E:706 ||| .
In  ||| S:706 E:709 ||| IN
general ||| S:709 E:716 ||| JJ
,  ||| S:716 E:718 ||| ,
patients  ||| S:718 E:727 ||| NNS
with  ||| S:727 E:732 ||| IN
RA  ||| S:732 E:735 ||| NNP
and  ||| S:735 E:739 ||| CC
AS  ||| S:739 E:742 ||| NNP
report  ||| S:742 E:749 ||| NN
significant  ||| S:749 E:761 ||| JJ
decrements  ||| S:761 E:772 ||| NN
in  ||| S:772 E:775 ||| IN
HRQoL  ||| S:775 E:781 ||| JJ
in  ||| S:781 E:784 ||| IN
comparison  ||| S:784 E:795 ||| NN
with  ||| S:795 E:800 ||| IN
the  ||| S:800 E:804 ||| DT
general  ||| S:804 E:812 ||| JJ
population ||| S:812 E:822 ||| NN
.  ||| S:822 E:824 ||| .
It  ||| S:824 E:827 ||| PRP
has  ||| S:827 E:831 ||| VBZ
been  ||| S:831 E:836 ||| VBN
shown  ||| S:836 E:842 ||| VBN
that  ||| S:842 E:847 ||| IN
the  ||| S:847 E:851 ||| DT
magnitude  ||| S:851 E:861 ||| NN
of  ||| S:861 E:864 ||| IN
the  ||| S:864 E:868 ||| DT
impairment  ||| S:868 E:879 ||| NN
is  ||| S:879 E:882 ||| VBZ
similar  ||| S:882 E:890 ||| JJ
among  ||| S:890 E:896 ||| IN
both  ||| S:896 E:901 ||| DT
patients  ||| S:901 E:910 ||| JJ
group ||| S:910 E:915 ||| NN
.  ||| S:915 E:917 ||| .
